Market Research Logo

Major Depressive Disorder - Current and Future Players

Major Depressive Disorder - Current and Future Players

Summary

GlobalData has released its pharma report, “Major Depressive Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MDD Market. The report identifies and analyses the key companies shaping and driving the global MDD market. The report provides insight into the competitive MDD landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

  • Investigation of current and future market competition for MDD
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of MDD sector through market impact analysis, future market scenario and company analysis
Reasons to buy
  • Gain a high level view of the trends shaping and driving MDD market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What’s the next big thing in the global MDD market landscape? Identify, understand and capitalize


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Related Reports
2.2 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers - Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 Allergan
4.3.2 e-Therapeutics
4.3.3 Alkermes
4.3.4 Pfizer
4.3.5 Otsuka
4.3.6 Janssen
4.3.7 Eli Lilly
4.3.8 Lundbeck
4.3.9 Takeda
4.3.10 Axsome Therapeutics
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Diagnosed NSCLC Patients
5.4.2 Percent Drug-Treated Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch and Patent Expiry Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Generic Erosion
5.4.8 Pricing of Pipeline Agents
5.5 Primary Research - KOLs
5.5.1 KOLs
5.6 About the Authors
5.6.1 Analyst
5.6.2 Therapy Area Director
5.6.3 Epidemiologist
5.6.4 Global Head of Healthcare
5.7 About GlobalData
5.8 Disclaimer
1.1 List of Tables
Table 1: MDD Market - Drivers and Barriers, 2015-2025
Table 2: Key Companies in the MDD Market in the 7MM
Table 3: Allergan’s MDD Portfolio Assessment, 2016
Table 4: Allergan SWOT Analysis in MDD, 2015-2025
Table 5: e-Therapeutics’ MDD Portfolio Assessment, 2016
Table 6: e-Therapeutics SWOT Analysis in MDD, 2015-2025
Table 7: Alkermes’ MDD Portfolio Assessment, 2016
Table 8: Alkermes SWOT Analysis in MDD, 2015-2025
Table 9: Pfizer’s MDD Portfolio Assessment, 2016
Table 10: Pfizer SWOT Analysis in MDD, 2015-2025
Table 11: Otsuka’s MDD Portfolio Assessment, 2016
Table 12: Otsuka SWOT Analysis in MDD, 2015-2025
Table 13: Janssen’s MDD Portfolio Assessment, 2016
Table 14: Janssen SWOT Analysis in MDD, 2015-2025
Table 15: Eli Lilly’s MDD Portfolio Assessment, 2016
Table 16: Eli Lilly SWOT Analysis in MDD, 2015-2025
Table 17: Lundbeck’s MDD Portfolio Assessment, 2016
Table 18: Lundbeck SWOT Analysis in MDD, 2015-2025
Table 19: Takeda’s MDD Portfolio Assessment, 2016
Table 20: Takeda SWOT Analysis in MDD, 2015-2025
Table 21: Axsome Therapeutics’ MDD Portfolio Assessment, 2016
Table 22: Axsome Therapeutics SWOT Analysis in MDD, 2015-2025
Table 23: Key Launch Dates - Part I
Table 24: Key Launch Dates - Part II
Table 25: Key Patent Expiries
Table 26 Average Body Weight and Surface Area Across the 8MM
Table 27: Average Cost of Therapy of Alimta in the 8MM
Table 28: Average Cost of Therapy of Alecensa in the 8MM
Table 29: Average Cost of Therapy of Avastin
Table 30: Average Cost of Therapy of Cyramza
Table 31: Average Cost of Therapy of Gilotrif
Table 32: Average Cost of Therapy of Iressa
Table 33: Average Cost of Therapy of Portrazza
Table 34: Average Cost of Therapy of Tagrisso
Table 35: Average Cost of Therapy of Tarceva
Table 36: Average Cost of Therapy of Vargatef
Table 37: Average Cost of Therapy of Xalkori
Table 38: Average Cost of Therapy of Zykadia
Table 39: Average Cost of Therapy of Keytruda
Table 40: Average Cost of Therapy of Opdivo
Table 41: Average Cost of Therapy of Tecentriq
Table 42: Average Cost of Therapy of Conmana
Table 43: High-Prescribing Physicians Surveyed by Country
1.2 List of Figures
Figure 1: Global Sales by Region for MDD Therapies, 2015 and 2025
Figure 2: Global Sales by Region for MDD Therapies, 2015-2025
Figure 3: Global Sales by Drug Class for MDD Therapies, 2015 and 2025
Figure 4: Global Sales by Drug Class for MDD Therapies, 2015-2025
Figure 5: Company Portfolio Gap Analysis in MDD, 2015-2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report